The U.S. Food and Drug Administration (FDA) has issued a detailed warning about the risks associated with unapproved and compounded GLP-1 drugs being used for weight loss, highlighting concerns related to product quality, dosing errors, counterfeit medicines and improper storage.

Gland Pharma Limited has announced the successful conclusion of a routine Good Manufacturing Practice (GMP) inspection conducted by the United States Food and Drug Administration (USFDA) at its facilities in Visakhapatnam.

The inspection was carried out at the company’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam. The regulatory inspection commenced on August 24, 2026, and concluded on September 1, 2026.

A new study published in Acta Clinica Belgica has found that vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) can produce substantial tumor shrinkage in patients with metastatic clear-cell renal cell carcinoma (ccRCC) involving the pancreas.

The Advanced Research Projects Agency for Health (ARPA-H) has selected five research teams to develop new technologies aimed at making individualized, RNA-based genetic medicines faster and more accessible.

The initiative is part of ARPA-H’s Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, which could receive up to 125 million USD in research and development funding. The program seeks to establish an automated, distributed manufacturing network capable of producing genetic medicines on demand and closer to the point of care.